Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab vs Mepolizumab in EGPA (Japan, 52-week randomized trial with open-label extension)
jRCT2080224961Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Benralizumab arm with Mepolizumab arm (2 arms). Started Nov 2019; status: completed.
02
Drugs
benralizumabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT2080224961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224961.